Furthermore, the STING-TBK1-IRF3 pathway was suggested as a driver of the anti-tumor activity when targeting DDR, which increased the levels of the chemokines CXCL10 and CCL5, responsible for the activation and function of cytotoxic T cells [189]. This evidence concerns the gene STING1 and neoplasm.